BOLT — Bolt Biotherapeutics Share News
0.000.00%
Last trade - 00:00- $12.08m
- -$5.52m
- $7.70m
Bolt Biotherapeutics Inc expected to post a loss of 36 cents a share - Earnings Preview
Bolt Biotherapeutics Inc reports results for the quarter ended December 31 - Earnings Summary
Bolt Biotherapeutics Inc expected to post a loss of 34 cents a share - Earnings Preview
Bolt Biotherapeutics Inc expected to post a loss of 38 cents a share - Earnings Preview
Brief: Bolt Biotherapeutics Inc - On Jan 2, Co's Transfer To Nasdaq Capital Market Approved
Bolt Biotherapeutics Inc reports results for the quarter ended September 30 - Earnings Summary
Bolt Biotherapeutics Inc expected to post a loss of 33 cents a share - Earnings Preview
Brief: Bolt Announces The Availability Of Its Enterprise Product On Salesforce AppExchange
Bolt Biotherapeutics Inc reports results for the quarter ended in June - Earnings Summary
Bolt Biotherapeutics Inc expected to post a loss of 30 cents a share - Earnings Preview
Bolt Biotherapeutics Inc expected to post a loss of 48 cents a share - Earnings Preview
U.S. STOCKS ON THE MOVE-MakeMyTrip, WaFd, Bolt Biotherapeutics
Bolt Biotherapeutics falls after scrapping lead drug development
Bolt Biotherapeutics Inc reports results for the quarter ended in March - Earnings Summary
U.S. RESEARCH ROUNDUP- Altus Power, Jack in the Box, Home Depot
U.S. RESEARCH ROUNDUP- Altus Power, Jack in the Box, Home Depot
Bolt Biotherapeutics Inc expected to post a loss of 51 cents a share - Earnings Preview
Brief: Pacira Appoints Frank D. Lee As Chief Executive Officer
Brief: Bolt Biotherapeutics Enrolls First Patient in Phase 2 Clinical Study Evaluating BDC-1001 in Patients with HER2-Positive Breast Cancer Previously Treated with Enhertu®